Literature DB >> 26754738

Characterization of the peptide binding specificity of the HLA class I alleles B*38:01 and B*39:06.

John Sidney1, Jennifer Schloss2, Carrie Moore1, Mikaela Lindvall1, Amanda Wriston3, Donald F Hunt4, Jeffrey Shabanowitz3, Teresa P DiLorenzo2,5, Alessandro Sette6.   

Abstract

B*38:01 and B*39:06 are present with phenotypic frequencies <2% in the general population, but are of interest as B*39:06 is the B allele most associated with type 1 diabetes susceptibility and 38:01 is most protective. A previous study derived putative main anchor motifs for both alleles based on peptide elution data. The present study has utilized panels of single amino acid substitution peptide libraries to derive detailed quantitative motifs accounting for both primary and secondary influences on peptide binding. From these analyses, both alleles were confirmed to utilize the canonical position 2/C-terminus main anchor spacing. B*38:01 preferentially bound peptides with the positively charged or polar residues H, R, and Q in position 2 and the large hydrophobic residues I, F, L, W, and M at the C-terminus. B*39:06 had a similar preference for R in position 2, but also well-tolerated M, Q, and K. A more dramatic contrast between the two alleles was noted at the C-terminus, where the specificity of B*39:06 was clearly for small residues, with A as most preferred, followed by G, V, S, T, and I. Detailed position-by-position and residue-by-residue coefficient values were generated from the panels to provide detailed quantitative B*38:01 and B*39:06 motifs. It is hoped that these detailed motifs will facilitate the identification of T cell epitopes recognized in the context of two class I alleles associated with dramatically different dispositions towards type 1 diabetes, offering potential avenues for the investigation of the role of CD8 T cells in this disease.

Entities:  

Keywords:  Antigen presentation; Epitopes; Major histocompatibility complex; Type 1 diabetes

Mesh:

Substances:

Year:  2016        PMID: 26754738      PMCID: PMC4760861          DOI: 10.1007/s00251-015-0898-2

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   3.330


  37 in total

Review 1.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.

Authors:  Alessandro Sette; John Fikes
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

2.  Comparative study of the residues 63 and 67 on the HLA-B molecule in patients with Takayasu's Arteritis.

Authors:  Gilberto Vargas-Alarcón; Guadalupe Hernández-Pacheco; Maria Elena Soto; Luis Enrique Murguía; Nonanzit Pérez-Hernández; Julio Granados; Pedro A Reyes
Journal:  Immunol Lett       Date:  2005-01-31       Impact factor: 3.685

Review 3.  Immune epitope mapping in the post-genomic era: lessons for vaccine development.

Authors:  Alessandro Sette; Bjoern Peters
Journal:  Curr Opin Immunol       Date:  2006-11-17       Impact factor: 7.486

4.  Automated benchmarking of peptide-MHC class I binding predictions.

Authors:  Thomas Trolle; Imir G Metushi; Jason A Greenbaum; Yohan Kim; John Sidney; Ole Lund; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-02-25       Impact factor: 6.937

5.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

6.  Association of human leukocyte antigen class I antigens in Iranian patients with pemphigus vulgaris.

Authors:  Hossein Mortazavi; Ali Akbar Amirzargar; Nafiseh Esmaili; Hesam Toofan; Amir Hooshang Ehsani; Seyed Hamed Hosseini; Nima Rezaei
Journal:  J Dermatol       Date:  2013-01-21       Impact factor: 4.005

7.  Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.

Authors:  Denise L Doolan; Scott Southwood; Daniel A Freilich; John Sidney; Norma L Graber; Lori Shatney; Lolita Bebris; Laurence Florens; Carlota Dobano; Adam A Witney; Ettore Appella; Stephen L Hoffman; John R Yates; Daniel J Carucci; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-28       Impact factor: 11.205

Review 8.  Reverse vaccinology: developing vaccines in the era of genomics.

Authors:  Alessandro Sette; Rino Rappuoli
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

9.  HLA class I supertypes: a revised and updated classification.

Authors:  John Sidney; Bjoern Peters; Nicole Frahm; Christian Brander; Alessandro Sette
Journal:  BMC Immunol       Date:  2008-01-22       Impact factor: 3.615

10.  Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.

Authors:  Sergey Nejentsev; Joanna M M Howson; Neil M Walker; Jeffrey Szeszko; Sarah F Field; Helen E Stevens; Pamela Reynolds; Matthew Hardy; Erna King; Jennifer Masters; John Hulme; Lisa M Maier; Deborah Smyth; Rebecca Bailey; Jason D Cooper; Gloria Ribas; R Duncan Campbell; David G Clayton; John A Todd
Journal:  Nature       Date:  2007-11-14       Impact factor: 49.962

View more
  3 in total

1.  HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression.

Authors:  Jennifer Schloss; Riyasat Ali; Jeremy J Racine; Harold D Chapman; David V Serreze; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

2.  Protein nanovaccine confers robust immunity against Toxoplasma.

Authors:  Kamal El Bissati; Ying Zhou; Sara Maria Paulillo; Senthil Kumar Raman; Christopher P Karch; Craig W Roberts; David E Lanar; Steve Reed; Chris Fox; Darrick Carter; Jeff Alexander; Alessandro Sette; John Sidney; Hernan Lorenzi; Ian J Begeman; Peter Burkhard; Rima McLeod
Journal:  NPJ Vaccines       Date:  2017-09-05       Impact factor: 7.344

3.  Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.

Authors:  Weilong Zhao; Xinwei Sher
Journal:  PLoS Comput Biol       Date:  2018-11-08       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.